Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ATNM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ATNM

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Actinium Pharmaceuticals Inc

ATNM
Current price
1.52 USD -0.03 USD (-1.94%)
Last closed 1.55 USD
ISIN US00507W2061
Sector Healthcare
Industry Biotechnology
Exchange NYSE
Capitalization 48 353 644 USD
Yield for 12 month -80.13 %
1Y
3Y
5Y
10Y
15Y
ATNM
21.11.2021 - 28.11.2021

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York. Address: 100 Park Avenue, New York, NY, United States, 10017

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.00 USD

P/E Ratio

Dividend Yield

Financials ATNM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ATNM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

+81 000 USD

Current Quarter

Last Quarter

Current Year

Last Year

+81 000 USD

Current Quarter

Last Quarter

EBITDA -48 966 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -39.14 %
PEG Ratio
Return On Equity TTM -130.87 %
Wall Street Target Price 5.00 USD
Revenue TTM 81 000 USD
Book Value 0.82 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM 81 000 USD
Earnings per share -1.47 USD
Diluted Eps TTM -1.47 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation ATNM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 6.84
Enterprise Value Revenue 1 726.07
Price Sales TTM 652.71
Enterprise Value EBITDA -3.62
Price Book MRQ 1.92

Technical Indicators ATNM

For 52 Weeks

1.03 USD 8.64 USD
50 Day MA 1.57 USD
Shares Short Prior Month 1 827 890
200 Day MA 1.46 USD
Short Ratio 5.57
Shares Short 1 434 399
Short Percent 4.60 %